SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ -- IASO Biotherapeutics ('IASO Bio'), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced a new set of collaborations with Umoja Biopharma, Inc.

加利福尼亚州圣何塞，中国上海和南京，2024年1月3日/PRNewswire/--IASO Biotherapeutics（“IASO Bio”），一家从事发现，开发，制造和营销创新细胞疗法和抗体产品的生物制药公司，今天宣布与Umoja Biopharma，Inc.进行一系列新的合作。

('Umoja'), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, for the development and commercialization of novel ex vivo and in vivo cell and gene therapies..

（“Umoja”），一家变革性免疫治疗公司，创建现成的治疗方法，旨在扩大CAR-T细胞疗法在肿瘤学和自身免疫中的范围和有效性，以开发和商业化新型离体和体内细胞和基因疗法。。

Under the terms of the collaborations, IASO Bio will receive exclusive access to the rapamycin-activated cytokine receptor (RACR™) platform, Umoja's synthetic cytokine receptor technology, for the development of two ex vivo iPSC-derived chimeric antigen receptor (CAR)-bearing cell therapies. IASO will be responsible for worldwide product development, manufacturing, regulatory and commercialization of both ex vivo products.

根据合作条款，IASO Bio将独家获得雷帕霉素激活的细胞因子受体（RACR™) 平台，Umoja的合成细胞因子受体技术，用于开发两种离体iPSC衍生的嵌合抗原受体（CAR）携带细胞疗法。IASO将负责两种离体产品的全球产品开发、制造、监管和商业化。

In exchange, Umoja will receive exclusive rights to CAR cassettes for two targets for the advancement of two in vivo product candidates incorporating VivoVec™, Umoja's proprietary lentiviral in vivo gene delivery technology. Umoja will be responsible for product development, manufacturing, regulatory and commercialization in territories outside of Greater China, and IASO for the Greater China territory.  In addition, each party is entitled to customary development and sales milestones and royalties in the relevant collaborations.

作为交换，Umoja将获得两个目标的车载磁带专有权，以促进两个结合VivoVec的体内候选产品的发展™, Umoja专有的慢病毒体内基因传递技术。“团结”将负责大中华区以外地区的产品开发、制造、监管和商业化，并负责大中华区的IASO。此外，各方有权在相关合作中获得惯常的开发和销售里程碑以及版税。

Collectively, this set of collaborations seeks to advance off-the-shelf cell and gene therapies that are rooted in innovative scientific advancements with applications in oncology and immunology..

总的来说，这组合作旨在推进现成的细胞和基因疗法，这些疗法植根于创新的科学进步，并应用于肿瘤学和免疫学。。

Alan Fu, Chief Financial Officer of IASO Bio, stated, 'We are excited to collaborate with Umoja on the investigation and development of our allogeneic cell therapies.  By combining Umoja's RACR platform, which aims to improve the patient experience by removing the need for lymphodepletion while also optimizing product development through improved cell differentiation and scalability, with our validated CAR constructs, we aim to bring novel allogeneic treatments to patients globally who are underserved by current therapies.

IASO Bio首席财务官Alan Fu表示，“我们很高兴与Umoja合作，研究和开发我们的同种异体细胞疗法。通过将Umoja的RACR平台与我们经过验证的CAR构建体相结合，我们的目标是通过消除淋巴清除的需求来改善患者体验，同时通过改善细胞分化和可扩展性来优化产品开发，为全球范围内目前治疗服务不足的患者带来新的同种异体治疗。

Additionally, Umoja gains access to our clinically validated best-in-class CAR constructs to advance their in vivo CAR-T therapeutics with the potential to fundamentally transform the cell and gene therapy treatment landscape for patients.'.

此外，Umoja获得了我们临床验证的同类最佳CAR构建体的使用权，以推进其体内CAR-T治疗，并有可能从根本上改变患者的细胞和基因治疗前景。”。

'This agreement advances two complementary approaches that embody Umoja and IASO Bio's shared commitment to making cell therapies more accessible to patients. Together, we are pushing beyond traditional development and collaboration approaches to realize the full potential of CAR-T cell therapies,' added Umoja's Chief Operating and Chief Business Officer, David Fontana, PhD.

“该协议推进了两种互补的方法，体现了Umoja和IASO Bio共同致力于使患者更容易获得细胞疗法。“团结”的首席运营官兼首席商务官DavidFontana博士补充道，我们正在超越传统的开发和合作方法，以充分发挥CAR-T细胞疗法的潜力。

'By incorporating IASO's best-in-class CARs with Umoja's VivoVec technology, we have the opportunity to expand the potential reach of our in vivo gene delivery technology to new indications and provide much needed options for patients who need them.'.

“通过将IASO一流的CAR与Umoja的VivoVec技术相结合，我们有机会将体内基因传递技术的潜在范围扩大到新的适应症，并为需要它们的患者提供急需的选择。”。

About IASO Bio

关于IASO Bio

IASO Bio is a biopharmaceutical company engaged in the discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercial production..

IASO Bio是一家生物制药公司，致力于发现和开发用于肿瘤学和自身免疫性疾病的新型细胞疗法和生物制剂。IASO Bio拥有跨越整个药物开发过程的综合能力，从早期发现到临床开发，监管批准和商业生产。。

The pipeline in the company includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S.

该公司的产品线包括10多种新产品的多元化组合，包括Equecabtagene Autoleucel（一种全人类BCMA CAR-T注射剂）。Equecabtagene Autoleucel获得了中国国家医药产品管理局（NMPA）和美国的新药申请（NDA）批准。

FDA IND approval for the treatment of RR MM..

FDA IND批准用于治疗RR MM。。

Leveraging its strong management team, innovative product pipeline, GMP production, as well as integrated manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China as well as around the world. For more information, please visit http://www.iasobio.com or www.linkedin.com/company/iasobiotherapeutics..

IASO凭借其强大的管理团队、创新的产品线、GMP生产以及集成的制造和临床能力，旨在为中国以及世界各地的患者提供变革性、可治愈和负担得起的治疗方法，以满足未满足的医疗需求。有关更多信息，请访问http://www.iasobio.com或www.linkedin.com/company/iasobiotherapeutics。。

About Umoja Biopharma

关于团结项目生物制药

Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja's VivoVec™ in vivo gene delivery technology empowers a patient's own immune system to fight disease.

Umoja Biopharma，Inc.是一家临床阶段生物技术公司，旨在开发现成的治疗方法，以提高CAR T细胞疗法在肿瘤学和自身免疫中的应用范围，有效性和可及性。Umoja的VivoVec™ 体内基因传递技术使患者自身的免疫系统能够抵抗疾病。

Enabling its core technology is the Company's state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives.

使其核心技术得以实现的是该公司位于科罗拉多州路易斯维尔的最先进的慢病毒载体开发和制造设施。Umoja相信，它的方法可以提供更广泛的途径，提高最先进的免疫疗法的有效性，使更多的患者能够过上更好、更充实的生活。

To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/..

要了解更多信息，请在LinkedIn上与Umoja联系并访问http://umoja-biopharma.com/..

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Umoja Biopharma, Inc. (the 'Company,' 'we,' 'us,' or 'our'). The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs.

关于前瞻性声明的注意事项本新闻稿包含关于Umoja Biopharma，Inc.（以下简称“公司”、“我们”、“我们”或“我们”）的前瞻性声明。该公司的这些前瞻性报表主要基于其对未来事件和财务趋势的当前预期、估计、预测和预测，该公司认为这些未来事件和财务趋势可能会影响其财务状况、经营成果、业务战略和财务需求。

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as any economic, market and social disruptions.

鉴于这些前瞻性陈述中存在重大不确定性，您不应将前瞻性陈述视为对未来事件的预测。这些声明受到可能导致实际结果发生重大变化的风险和不确定性的影响，其中包括药物开发固有的风险，例如与公司当前和未来研发计划，临床前和临床试验以及任何经济，市场和社会混乱。

Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. .

除法律要求外，公司无义务以任何理由公开更新任何前瞻性声明。。

IASO Bio Contact:Alan Fu, JD, PhDChief Financial Officer[email protected]

IASO Bio联系人：Alan Fu，JD，PhDChief财务官[受电子邮件保护]

Umoja Media Contact:Karissa Cross, Ph.D.LifeSci Communications[email protected]

Umoja媒体联系人：Karissa Cross，Ph.D.LifeSci Communications[电子邮件保护]

SOURCE IASO BIO

查找您的来源